Clinical Oncology: Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Susanna Grassi Author

Subjects of specialization
cancer, cancer oncology, Carcinogenesis

Affiliation
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Biography

Dr. Susanna Grassi is working as scientist and professor at Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. The author has specalization in cancer, cancer oncology, chemotherapy, Carcinogenesis, Chemotherapy


Publications

Case Report Open Access

The Combination of Ponatinib and Alpha-Interferon can Improve Outcome of Resistant Chronic Myeloid Leukemia Patients

Author(s):

Claudia Barate*, Simona Soverini, Elisabetta Abruzzese, Francesca Guerrini, Susanna Grassi, Maria Immacolata Ferreri, Federica Ricci, Serena Balducci, Mario Petrini and Sara Galimberti

Abstract

The most of patients affected by chronic myeloid leukemia is cured with Tyrosine Kinase Inhibitors (TKI). However, about 30% must change therapies for intolerance or poor efficacy. The failure of therapy is associated in the majority of cases to the appearance of ABL1 mutations. Ponatinib (ICLUSIG, INCYTE®) is able to overcome most of the known mutations, including the T315I. But when compound mutations appear, the TKIs alone are not enough and a combination therapy is required to overcome this condition.

We describe here the evolution of the mutational status of 3 patients with compound mutations, treated with the association of ponatinib plus alfa interferon. This combination resulted safe and effective for all.

In... view moreĀ»

Abstract HTML PDF



Google Scholars / Researchers Sites

GET THE APP